

Maria Sepulveda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3869728/publications.pdf>

Version: 2024-02-01

59
papers

2,745
citations

236925

25
h-index

189892

50
g-index

60
all docs

60
docs citations

60
times ranked

3326
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. <i>Multiple Sclerosis Journal</i> , 2015, 21, 866-874.	3.0	241
2	Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. <i>Lancet Neurology</i> , The, 2020, 19, 234-246.	10.2	207
3	Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. <i>Annals of Neurology</i> , 2014, 75, 98-107.	5.3	206
4	Neuromyelitis optica spectrum disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e225.	6.0	134
5	Randomized Placebo-Controlled Phase II Trial of Autologous Mesenchymal Stem Cells in Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e113936.	2.5	131
6	Antibodies to Aquaporin 4, Myelin-Oligodendrocyte Glycoprotein, and the Glycine Receptor $\alpha 1$ Subunit in Patients With Isolated Optic Neuritis. <i>JAMA Neurology</i> , 2015, 72, 187.	9.0	119
7	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 134.	7.2	115
8	Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. <i>Journal of Neurology</i> , 2016, 263, 1349-1360.	3.6	112
9	Worldwide Incidence and Prevalence of Neuromyelitis Optica. <i>Neurology</i> , 2021, 96, 59-77.	1.1	101
10	Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. <i>Neurology</i> , 2020, 94, e2302-e2310.	1.1	94
11	Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1257-1259.	1.9	89
12	Structural networks involved in attention and executive functions in multiple sclerosis. <i>NeuroImage: Clinical</i> , 2017, 13, 288-296.	2.7	87
13	Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications. <i>Multiple Sclerosis Journal</i> , 2016, 22, 312-319.	3.0	79
14	Acute stroke unit care and early neurological deterioration in ischemic stroke. <i>Journal of Neurology</i> , 2008, 255, 1012-1017.	3.6	77
15	Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1843-1851.	3.0	77
16	Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1753-1759.	3.0	71
17	Influence of Corpus Callosum Damage on Cognition and Physical Disability in Multiple Sclerosis: A Multimodal Study. <i>PLoS ONE</i> , 2012, 7, e37167.	2.5	68
18	Cognitive functions in multiple sclerosis: impact of gray matter integrity. <i>Multiple Sclerosis Journal</i> , 2014, 20, 424-432.	3.0	47

#	ARTICLE	IF	CITATIONS
19	Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. <i>Journal of Neurology</i> , 2019, 266, 806-815.	3.6	47
20	Late-onset neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	6.0	44
21	Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 436-440.	3.5	43
22	Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 564-568.	3.0	36
23	Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 742-748.	3.0	35
24	Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 1246.	9.0	32
25	Incidence and Impact of COVID-19 in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	29
26	Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101483.	2.0	23
27	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. <i>Journal of Autoimmunity</i> , 2021, 117, 102580.	6.5	23
28	Retrograde retinal damage after acute optic tract lesion in MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 824-826.	1.9	22
29	Magnetic resonance markers of tissue damage related to connectivity disruption in multiple sclerosis. <i>NeuroImage: Clinical</i> , 2018, 20, 161-168.	2.7	22
30	Analysis of antibodies to surface epitopes of contactin-2 in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2012, 244, 103-106.	2.3	21
31	Predictors of vision impairment in Multiple Sclerosis. <i>PLoS ONE</i> , 2018, 13, e0195856.	2.5	21
32	Cortical fractal dimension predicts disability worsening in Multiple Sclerosis patients. <i>NeuroImage: Clinical</i> , 2021, 30, 102653.	2.7	21
33	Risk factors of severe COVID-19 in people with multiple sclerosis : A systematic review and meta-analysis. <i>Revue Neurologique</i> , 2022, 178, 121-128.	1.5	21
34	Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years. <i>Scientific Reports</i> , 2020, 10, 13333.	3.3	20
35	Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma. <i>Muscle and Nerve</i> , 2017, 56, E162-E167.	2.2	18
36	Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 230-234.	2.0	18

#	ARTICLE	IF	CITATIONS
37	Spanish validation of the telephone assessed Expanded Disability Status Scale and Patient Determined Disease Steps in people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 333-339.	2.0	17
38	Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 234.	9.0	17
39	Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients. <i>Scientific Reports</i> , 2021, 11, 16805.	3.3	17
40	Telemedicine for Monitoring MS Activity and Progression. <i>Current Treatment Options in Neurology</i> , 2015, 17, 47.	1.8	15
41	Visual field impairment captures disease burden in multiple sclerosis. <i>Journal of Neurology</i> , 2016, 263, 695-702.	3.6	14
42	Characterization of multiple sclerosis lesions with distinct clinical correlates through quantitative diffusion MRI. <i>NeuroImage: Clinical</i> , 2020, 28, 102411.	2.7	11
43	Modified connectivity of vulnerable brain nodes in multiple sclerosis, their impact on cognition and their discriminative value. <i>Scientific Reports</i> , 2019, 9, 20172.	3.3	10
44	Applying multilayer analysis to morphological, structural, and functional brain networks to identify relevant dysfunction patterns. <i>Network Neuroscience</i> , 2022, 6, 916-933.	2.6	10
45	Liver injury and glatiramer acetate, an uncommon association: case report and literature review. <i>Therapeutic Advances in Neurological Disorders</i> , 2017, 10, 367-372.	3.5	9
46	Impairment of decision-making in multiple sclerosis: A neuroeconomic approach. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1762-1771.	3.0	8
47	Impact of Cognitive Reserve and Structural Connectivity on Cognitive Performance in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 581700.	2.4	8
48	Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1706-1716.	3.0	8
49	Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 713-719.	1.8	8
50	Dynamics and Predictors of Cognitive Impairment along the Disease Course in Multiple Sclerosis. <i>Journal of Personalized Medicine</i> , 2021, 11, 1107.	2.5	8
51	Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641878000.	3.5	7
52	Adult onset Pompe disease associated with multiple sclerosis. <i>Journal of Neurology</i> , 2011, 258, 2286-2287.	3.6	6
53	Long-term follow-up of immunotherapy-unresponsive recurrent tumefactive demyelination. <i>Journal of the Neurological Sciences</i> , 2015, 352, 127-128.	0.6	6
54	Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder. <i>Journal of Personalized Medicine</i> , 2022, 12, 743.	2.5	6

#	ARTICLE	IF	CITATIONS
55	Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report. <i>Journal of Neurology</i> , 2015, 262, 219-221.	3.6	3
56	Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study. <i>Neurology and Therapy</i> , 2022, 11, 1101-1116.	3.2	3
57	Aquaporin-4-Positive Triple-Negative Breast Cancer Presenting with Paraneoplastic Neuromyelitis Optica Spectrum Disorder. <i>Biomedicine Hub</i> , 2022, 7, 11-16.	1.2	2
58	Vanishing spinal cord after varicella-zoster virus myelitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e364.	6.0	1
59	Quantifying the patient's perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire. <i>PLoS ONE</i> , 2021, 16, e0255317.	2.5	0